bioRxiv Science⌕ Search

Biology subjects

Matter, M.

Publications and source records attributed to Matter, M..

4 recordsLinked to original sources

Multimodal single-cell profiling of T cell specificity and reactivity in lung cancer

Adoptive transfer of autologous tumor-infiltrating lymphocyte T cells (TILs) offers one of the most promising approaches for cancer immunotherapy. However, high variability in patient responses highlight the need for an enhanced understanding of the transcriptional phenotypes of TILs and reactivity of their T cell receptors (TCR). Here, we employ single-cell multiomics approaches and TCR functional screening to investigate TILs from treatment-naive non-small cell lung cancer patients. This comprehensive analysis integrates scRNA-seq, scTCR-seq, and scATAC-seq, enabling a high-resolution examination of TILs within lung cancer tissue, as well as the adjacent non-tumor tissue. We apply a cellular functional screening platform to identify reactive TCRs that represent >1,000 TILs and have specificity towards a multitude of targets, including primary tumor cells, neoantigens, tumor-associated antigens, and viral antigens. Tumor-reactive TILs were primarily associated with dysfunctional phenotypes, whereas viral antigen-reactive TCRs were found in effector phenotype clusters. Key marker genes were identified and used to construct a tumor or viral reactivity score. Comparing clones shared in tumor and non-tumor tissue, a higher fraction of exhausted cells was observed in the tumor tissue, whereas non-tumor adjacent tissue possessed more effector cells, thus providing insight into potential sources for therapeutic T cells. Elucidating the specific T cell populations within TILs and their associated TCRs may support strategies to enhance the efficacy of TIL-based therapies. Graphical AbstractO_ST_ABSMultimodal single cell profiling and reactivity testing of TILsC_ST_ABS(A) CD8+ T cells of treatment naive non-small cell lung cancer patients and adjacent lung tissue were isolated by fluorescence-activated cell sorting (FACS) and were then subjected to scRNA-seq + scTCR-seq or scATAC-seq. (B) TCRs were functionally screened using a cellular platform (TnT cells) and target cells (tumor cells, antigen-pulsed antigen-presenting cells, PBMCs) by flow cytometry and deep sequencing. (C) scRNA-seq + scATAC-seq allowed trajectory inference of transcription factors and genes along pseudotime. (D) Gene scores for tumor- and virus-reactivity were developed by combining functional reactivity and transcriptomic profiling for each CD8+ T cell. (E) TIL scRNA-seq pre and post IL-2 treatment in tumor suspension displayed as alluvial plot shows change of clonal cell state composition. O_FIG O_LINKSMALLFIG WIDTH=196 HEIGHT=200 SRC="FIGDIR/small/560863v1_ufig1.gif" ALT="Figure 1"> View larger version (51K): org.highwire.dtl.DTLVardef@12fcc20org.highwire.dtl.DTLVardef@1027dccorg.highwire.dtl.DTLVardef@911711org.highwire.dtl.DTLVardef@18171e5_HPS_FORMAT_FIGEXP M_FIG C_FIG

immunology↗

A human omentum-specific mesothelial-like stromal population inhibits adipogenesis through IGFBP2 secretion

Adipose tissue plasticity is orchestrated by molecularly and functionally diverse cells within the stromal vascular fraction (SVF). While several mouse and human adipose SVF cellular subpopulations have now been identified, we still lack an understanding of the cellular and functional variability of adipose stem and progenitor cell (ASPC) populations across human fat depots. To address this, we performed single-cell and bulk RNA-seq analyses of >30 Lin-SVF samples across four human adipose depots, revealing two ubiquitous hASPC subpopulations with distinct proliferative and adipogenic properties but also depot- and BMI-dependent proportions. Furthermore, we identified an omental-specific, high IGFBP2- expressing stromal population that transitions between mesothelial and mesenchymal cell states and inhibits hASPC adipogenesis through IGFBP2 secretion. Our analyses highlight the molecular and cellular uniqueness of different adipose niches while our discovery of an anti-adipogenic IGFBP2+ omental-specific population provides a new rationale for the biomedically relevant, limited adipogenic capacity of omental hASPCs.

cell biology↗

Multidimensional analysis of matched primary and recurrent glioblastoma identifies Fcgamma receptors upregulation on microglia as a contributor of tumor recurrence.

O_LIBackground: Glioblastoma (GBM) is a lethal brain tumor without effective treatment options. The aim of this study was to characterize longitudinal tumor immune microenvironment (iTME) changes in order to find potential actionable targets to prevent GBM-induced immune evasion mechanisms. C_LIO_LIMethods: This study included 15 patient-matched treatment-naive WHO grade 4 primary (pGBM) and recurrent (rGBM) tumors. RNA and proteins extracted from fresh frozen tumor samples from matched pGBM and rGBM were profiled via transcriptomics and proteomics, respectively. A tissue microarray containing paired formalin-fixed paraffin-embedded tumor samples was processed for spatial transcriptomics analysis. C_LIO_LIResults: Differentially expressed genes and proteins between pGBM and rGBM were involved in pathways responsible for synapse development and myelination which have been shown to play a role in GBM recurrence. By categorizing patients into short and long time-to-relapse (STTR vs LTTR), we identified genes positively or negatively associated with TTR. Expression of Fc{gamma} receptors and complement system genes such as FCGR1A (CD64), FCGR3A and C3 in rGBM samples were negatively correlated with TTR, whereas expression of DNMT1/3A, and SMARCA4, involved in DNA methylation, were positively correlated with TTR. Spatial transcriptomic analysis of the tumor cell compartment showed enrichment of oligodendrocytes in rGBM, whereas the myeloid cell compartment switched from quiescent to activated microglia, was enriched in B and T cells, specifically in rGBM with STTR. C_LIO_LIConclusions: Our results uncover a role for CD64-expressing activated microglia in GBM recurrence and suggest that interfering with these cells may represent a therapeutic option for hindering GBM relapse. C_LI Key pointsO_LITranscriptomic and proteomic differences exist between patient-paired primary and recurrent GBM tumors C_LIO_LIHigh expression of Fcy receptors genes on activated microglia at tumor recurrence is associated with shorter time to relapse. C_LI Importance of this studyIn glioblastoma (GBM), the tumor recurs in almost all cases after standard treatment such as surgery and chemo-radiotherapy. In this study, we longitudinally evaluated the immune- and neoplastic compartments using transcriptomic, proteomic, and spatial transcriptomics in patient-matched treatment-naive and recurrent tumor samples. By correlating gene expression with time-to-relapse, we identified a geneset associated with treatment resistance and faster tumor recurrence. Moreover, this study highlighted the plasticity of the myeloid compartment during disease progression and an unfavorable role of activated microglia in tumor recurrence.

cancer biology↗

Tumor Microenvironment Cellular Crosstalk Predicts Response to Adoptive TIL Therapy in Melanoma

Adoptive cell therapy (ACT) using ex vivo expanded tumor-infiltrating T lymphocytes (TILs) can mediate responses in metastatic melanoma, but long-term efficacy remains limited to a fraction of patients. Here we interrogated tumor-microenvironment (TME) cellular states and interactions of longitudinal samples from 13 metastatic melanoma patients treated with TIL-ACT in our clinical study (NCT03475134). We performed single-cell RNA-seq and spatial proteomic analyses in pre- and post-ACT tumor tissues and showed that responders exhibited higher tumor cell-intrinsic immunogenicity. Also, endogenous CD8+ TILs and myeloid cells of responders were characterized by increased cytotoxicity, exhaustion and costimulation and type-I IFN signaling, respectively. Cell-cell interaction prediction analyses corroborated by spatial neighborhood analyses revealed that responders have rich baseline intratumoral and stromal tumor-reactive T-cell networks with activated myeloid populations. Successful TIL-ACT therapy further reprogrammed the myeloid compartment and increased TIL-myeloid networks. Our systematic target discovery study reveals CD8+ T-cell network-based biomarkers that could improve patient selection and guide the design of ACT clinical trials. One-Sentence SummaryResponse to adoptive TIL therapy in melanoma is determined by CD8+ TIL-myeloid cell networks

immunology↗